Monument Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Monument Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,000	Closed	-$7K	–	255
2018 Q3	$7K	Hold	1,000	–	–	﹤0.01%	184
2018 Q2	$7K	Hold	1,000	–	–	﹤0.01%	130
2018 Q1	$6K	Hold	1,000	–	–	﹤0.01%	125
2017 Q4	$4K	Buy	+1,000	New	+$5.11K	﹤0.01%	113

Other funds holding OCUL

Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

Monument Capital Management's OCUL Position: Q4 2018 in Review

Monument Capital Management sold out of Ocular Therapeutix (OCUL) in Q4 2018, closing a stake of 1,000 shares — an estimated $7K sold.

Monument Capital Management first reported a position in OCUL in Q4 2017 and held it in 4 quarters. The position peaked at $7K in Q3 2018. 69 funds tracked by Wall St. Rank hold OCUL as of Q4 2018.

Monument Capital Management reported no remaining Ocular Therapeutix position as of Q4 2018 after selling out during the quarter.
Monument Capital Management sold 1,000 Ocular Therapeutix shares in Q4 2018, an estimated $7K.
Monument Capital Management first reported a position in Ocular Therapeutix in Q4 2017 and held it in 4 quarters.
Monument Capital Management's Ocular Therapeutix position peaked at $7K in Q3 2018.
69 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q4 2018.

Based on Monument Capital Management's 13F filing for Q4 2018, filed 15 Jan 2019.